Nicholas A. Zachariades, Special Counsel, Mintz Levin Cohn Ferris Glovsky and Popeo PC to Speak at The Knowledge Group's Event
New York, NY, October 05, 2017 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Nicholas A. Zachariades, Special Counsel, Mintz Levin Cohn Ferris Glovsky and Popeo PC will speak at the Knowledge Congress’ webcast entitled: “Best Strategies and Practical Tips in Overcoming Biotech Patent Eligibility Rejections Lvie Webcast.” This event is scheduled for Tuesday, October 24, 2017 @ 3:00 PM to 5:00 PM (ET).
For further details, please visit:
https://www.theknowledgegroup.org/?p=28245
About Nicholas A. Zachariades
Nicholas is an attorney in Mintz Levin’s Boston office and provides patent opinion counseling and handles patent procurement for clients in the biotechnology and pharmaceutical industries. He has extensive experience in the areas of biotechnology, immunology, small molecules, molecular biology, regenerative medicine, virology, vaccines, and oncology. Nicholas has been practicing intellectual property law for 14 years. He has significant experience working with cutting-edge biomedical technology institutions and other clients — including major US universities, research institutes, start-ups, large- and medium-size US companies, and international corporations — and has handled a wide range of IP requirements, including patent drafting, patent prosecution, freedom-to-operate opinions, validity opinions, invalidity opinions, patentability opinions, infringement opinions, licensing, due diligence, and patentability assessments.
About Mintz Levin Cohn Ferris Glovsky and Popeo PC
Mintz Levin’s attorneys represent Fortune 500 companies, entrepreneurs, emerging growth and established companies, government agencies, and research institutes. The firm’s IP team handles all aspects of patents, trademarks, copyrights and trade secrets. The firm has deep experience preparing and prosecuting patents to issuance on clients’ most complex biologic and chemical patents. Mayo and other court rulings have made patenting certain kinds of biotech innovations more challenging, and Mintz Levin attorneys help clients achieve their desired patent protections even in light of these industry changes. The educational and professional backgrounds of Mintz Levin’s premier patent prosecution professionals ensure client technologies are deeply understood so the attorneys can provide technology-driven recommendations which enhance patent strategy. They understand the technology at the core of client innovations, are steeped in how court rulings are being applied, and are able to craft claims which survive USPTO scrutiny.
Event Synopsis:
Since its pivotal decisions on Alice Corp. v. CLS Bank last 2014, Assn. for Molecular Pathology v. Myriad Genetics Inc. and Mayo Collaborative Services v. Prometheus Laboratories, Inc. the United States Patent and Trademark Office (USPTO) has been stricter in granting patent eligibility for all types of technology, including biotech patents. Recent rejections under §101 pose an alarming situation for patent applicants, making them more cautious in their succeeding applications.
Listen as a distinguished patent professional team up with The Knowledge Group to provide the audience with the latest issues surrounding §101 eligibility rejections. Speakers will analyze, among other things, recent court decisions and rejections concerning biotech patent applications. They will also offer best practices and strategic tips in overcoming such rejections.
In a live webcast, the speakers will discuss:
Overview of Supreme Court's Decision on Alice Corp. v. CLS Bank, Assn. for Molecular Pathology v. Myriad Genetics Inc. and Mayo Collaborative Services v. Prometheus Laboratories, Inc.
Rejections under §101 since Alice Corp., Myriad and Prometheus
Lessons Learned from Recent Rejections
Steps in Assessing Patent Eligibility for Biotech Patents
· Best Practices and Strategic Tips
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Congress was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org/
For further details, please visit:
https://www.theknowledgegroup.org/?p=28245
About Nicholas A. Zachariades
Nicholas is an attorney in Mintz Levin’s Boston office and provides patent opinion counseling and handles patent procurement for clients in the biotechnology and pharmaceutical industries. He has extensive experience in the areas of biotechnology, immunology, small molecules, molecular biology, regenerative medicine, virology, vaccines, and oncology. Nicholas has been practicing intellectual property law for 14 years. He has significant experience working with cutting-edge biomedical technology institutions and other clients — including major US universities, research institutes, start-ups, large- and medium-size US companies, and international corporations — and has handled a wide range of IP requirements, including patent drafting, patent prosecution, freedom-to-operate opinions, validity opinions, invalidity opinions, patentability opinions, infringement opinions, licensing, due diligence, and patentability assessments.
About Mintz Levin Cohn Ferris Glovsky and Popeo PC
Mintz Levin’s attorneys represent Fortune 500 companies, entrepreneurs, emerging growth and established companies, government agencies, and research institutes. The firm’s IP team handles all aspects of patents, trademarks, copyrights and trade secrets. The firm has deep experience preparing and prosecuting patents to issuance on clients’ most complex biologic and chemical patents. Mayo and other court rulings have made patenting certain kinds of biotech innovations more challenging, and Mintz Levin attorneys help clients achieve their desired patent protections even in light of these industry changes. The educational and professional backgrounds of Mintz Levin’s premier patent prosecution professionals ensure client technologies are deeply understood so the attorneys can provide technology-driven recommendations which enhance patent strategy. They understand the technology at the core of client innovations, are steeped in how court rulings are being applied, and are able to craft claims which survive USPTO scrutiny.
Event Synopsis:
Since its pivotal decisions on Alice Corp. v. CLS Bank last 2014, Assn. for Molecular Pathology v. Myriad Genetics Inc. and Mayo Collaborative Services v. Prometheus Laboratories, Inc. the United States Patent and Trademark Office (USPTO) has been stricter in granting patent eligibility for all types of technology, including biotech patents. Recent rejections under §101 pose an alarming situation for patent applicants, making them more cautious in their succeeding applications.
Listen as a distinguished patent professional team up with The Knowledge Group to provide the audience with the latest issues surrounding §101 eligibility rejections. Speakers will analyze, among other things, recent court decisions and rejections concerning biotech patent applications. They will also offer best practices and strategic tips in overcoming such rejections.
In a live webcast, the speakers will discuss:
Overview of Supreme Court's Decision on Alice Corp. v. CLS Bank, Assn. for Molecular Pathology v. Myriad Genetics Inc. and Mayo Collaborative Services v. Prometheus Laboratories, Inc.
Rejections under §101 since Alice Corp., Myriad and Prometheus
Lessons Learned from Recent Rejections
Steps in Assessing Patent Eligibility for Biotech Patents
· Best Practices and Strategic Tips
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Congress was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org/
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories